Subarachnoid haemorrhage
Conditions
Interventions
Intervention group:Participants who are randomly allocated to the intervention group will receive 4g of taurine and be administered orally or through nasogastric tube immediately after enrolment and t
Placebo group:Participants who are randomly allocated to the placebo group will receive 4 capsules of indistinguishable placebo and be administered orally or through a nasogastric tube immediately aft
Sponsors
The Chinese University of Hong Kong, Prince of Wales Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Subarachnoid haemorrhage (aSAH) requiring ICU admission; 2. Aged >= 18 years.
Exclusion criteria
Exclusion criteria: 1. Admitted after elective coiling, stenting, or clipping of unruptured aneurysms 2. With mild aSAH not expected to stay in ICU for more than 24 hours 3. Not admitted for active neurosurgical and intensive care therapies or with life-support limitations 4. Hospitalised for more than 24 hours for aSAH 5. Who are pregnant 6. With significant renal impairment (eGFR <30 ml/min) (due to the body’s excretion of excess taurine through the kidneys) 7. Contraindications for nasogastric tube insertion (e.g., those who cannot take study capsules orally)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| S100B;Malondialdehyde (MDA);F2-isoprostanes;Plasma taurine;H2S level;Vasopasm;Gut microbiome diversity; | — |
Secondary
| Measure | Time frame |
|---|---|
| S100B;MDA;F2-isoprostanes;Seizures;Cerebral infarct;Neurological recovery;Mortality; | — |
Countries
China
Contacts
Public ContactKwok Ming HO
The Chinese University of Hong Kong, Prince of Wales Hospital
Outcome results
None listed